Literature DB >> 29980571

Erbin Suppresses KSR1-Mediated RAS/RAF Signaling and Tumorigenesis in Colorectal Cancer.

Payton D Stevens1, Yang-An Wen2, Xiaopeng Xiong2, Yekaterina Y Zaytseva3, Austin T Li4, Chi Wang2, Ashley T Stevens1, Trevor N Farmer2, Tong Gan2,5, Heidi L Weiss2, Masaki Inagaki6, Sylvie Marchetto7,8,9,10, Jean-Paul Borg7,8,9,10, Tianyan Gao11,2.   

Abstract

Erbin belongs to the LAP (leucine-rich repeat and PDZ domain) family of scaffolding proteins that plays important roles in orchestrating cell signaling. Here, we show that Erbin functions as a tumor suppressor in colorectal cancer. Analysis of Erbin expression in colorectal cancer patient specimens revealed that Erbin was downregulated at both mRNA and protein levels in tumor tissues. Knockdown of Erbin disrupted epithelial cell polarity and increased cell proliferation in 3D culture. In addition, silencing Erbin resulted in increased amplitude and duration of signaling through Akt and RAS/RAF pathways. Erbin loss induced epithelial-mesenchymal transition, which coincided with a significant increase in cell migration and invasion. Erbin interacted with kinase suppressor of Ras 1 (KSR1) and displaced it from the RAF/MEK/ERK complex to prevent signal propagation. Furthermore, genetic deletion of Erbin in Apc knockout mice promoted tumorigenesis and significantly reduced survival. Tumor organoids derived from Erbin/Apc double knockout mice displayed increased tumor initiation potential and activation of Wnt signaling. Results from gene set enrichment analysis revealed that Erbin expression associated positively with the E-cadherin adherens junction pathway and negatively with Wnt signaling in human colorectal cancer. Taken together, our study identifies Erbin as a negative regulator of tumor initiation and progression by suppressing Akt and RAS/RAF signaling in vivoSignificance: These findings establish the scaffold protein Erbin as a negative regulator of EMT and tumorigenesis in colorectal cancer through direct suppression of Akt and RAS/RAF signaling. Cancer Res; 78(17); 4839-52. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29980571      PMCID: PMC6510240          DOI: 10.1158/0008-5472.CAN-17-3629

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  50 in total

1.  The hemidesmosomal protein bullous pemphigoid antigen 1 and the integrin beta 4 subunit bind to ERBIN. Molecular cloning of multiple alternative splice variants of ERBIN and analysis of their tissue expression.

Authors:  B Favre; L Fontao; J Koster; R Shafaatian; F Jaunin; J H Saurat; A Sonnenberg; L Borradori
Journal:  J Biol Chem       Date:  2001-05-25       Impact factor: 5.157

Review 2.  Assembly of tight junctions during early vertebrate development.

Authors:  T P Fleming; T Papenbrock; I Fesenko; P Hausen; B Sheth
Journal:  Semin Cell Dev Biol       Date:  2000-08       Impact factor: 7.727

3.  PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth.

Authors:  Jianyu Liu; Payton D Stevens; Xin Li; Micheal D Schmidt; Tianyan Gao
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

4.  Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells.

Authors:  Reshma Rangwala; Fatima Banine; Jean-Paul Borg; Larry S Sherman
Journal:  J Biol Chem       Date:  2005-01-19       Impact factor: 5.157

5.  KSR stimulates Raf-1 activity in a kinase-independent manner.

Authors:  N R Michaud; M Therrien; A Cacace; L C Edsall; S Spiegel; G M Rubin; D K Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  Erbin is a negative modulator of cardiac hypertrophy.

Authors:  Inbal Rachmin; Sagi Tshori; Yoav Smith; Amit Oppenheim; Sylvie Marchetto; Gillian Kay; Roger S-Y Foo; Noa Dagan; Eliahu Golomb; Dan Gilon; Jean-Paul Borg; Ehud Razin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

Review 7.  Integrating signals from RTKs to ERK/MAPK.

Authors:  M M McKay; D K Morrison
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice.

Authors:  Xin Li; Payton D Stevens; Jianyu Liu; Haihua Yang; Wei Wang; Chi Wang; Zheng Zeng; Micheal D Schmidt; Mike Yang; Eun Y Lee; Tianyan Gao
Journal:  Gastroenterology       Date:  2014-02-11       Impact factor: 22.682

Review 9.  Epithelial cell polarity: a major gatekeeper against cancer?

Authors:  C Royer; X Lu
Journal:  Cell Death Differ       Date:  2011-05-27       Impact factor: 15.828

10.  Deficiency of Erbin induces resistance of cervical cancer cells to anoikis in a STAT3-dependent manner.

Authors:  Y Hu; H Chen; C Duan; D Liu; L Qian; Z Yang; L Guo; L Song; M Yu; M Hu; M Shi; N Guo
Journal:  Oncogenesis       Date:  2013-06-17       Impact factor: 7.485

View more
  14 in total

Review 1.  The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease.

Authors:  HyeIn Jang; Payton Stevens; Tianyan Gao; Emilia Galperin
Journal:  FEBS J       Date:  2020-07-06       Impact factor: 5.542

2.  The Appalachian Career Training in Oncology (ACTION) Program: Preparing Appalachian Kentucky High School and Undergraduate Students for Cancer Careers.

Authors:  Joshua R McConnell Parsons; Carol Hanley; Chris Prichard; Nathan L Vanderford
Journal:  J STEM Outreach       Date:  2021-12-20

Review 3.  Apical-basal polarity and the control of epithelial form and function.

Authors:  Clare E Buckley; Daniel St Johnston
Journal:  Nat Rev Mol Cell Biol       Date:  2022-04-19       Impact factor: 113.915

Review 4.  Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line.

Authors:  Silke Pudewell; Christoph Wittich; Neda S Kazemein Jasemi; Farhad Bazgir; Mohammad R Ahmadian
Journal:  Commun Biol       Date:  2021-06-08

5.  KSR1- and ERK-dependent translational regulation of the epithelial-to-mesenchymal transition.

Authors:  Chaitra Rao; Danielle E Frodyma; Siddesh Southekal; Robert A Svoboda; Adrian R Black; Chittibabu Guda; Tomohiro Mizutani; Hans Clevers; Keith R Johnson; Kurt W Fisher; Robert E Lewis
Journal:  Elife       Date:  2021-05-10       Impact factor: 8.140

6.  S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-κB positive feedback loop.

Authors:  Yiming Tu; Peng Xie; Xiaoliu Du; Liang Fan; Zhongyuan Bao; Guangchi Sun; Pengzhan Zhao; Honglu Chao; Chong Li; Ailiang Zeng; Minhong Pan; Jing Ji
Journal:  J Cell Mol Med       Date:  2019-08-20       Impact factor: 5.310

7.  Scribble, Erbin, and Lano redundantly regulate epithelial polarity and apical adhesion complex.

Authors:  Jongho Choi; Regina B Troyanovsky; Indrajyoti Indra; Brian J Mitchell; Sergey M Troyanovsky
Journal:  J Cell Biol       Date:  2019-05-30       Impact factor: 10.539

8.  Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.

Authors:  Zhi-Xuan Li; Zi-Qi Zheng; Zhuo-Hui Wei; Lu-Lu Zhang; Feng Li; Li Lin; Rui-Qi Liu; Xiao-Dan Huang; Jia-Wei Lv; Fo-Ping Chen; Xiao-Jun He; Jia-Li Guan; Jia Kou; Jun Ma; Guan-Qun Zhou; Ying Sun
Journal:  Theranostics       Date:  2019-10-14       Impact factor: 11.556

9.  Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors.

Authors:  Songlin Li; Yuan Yuan; He Xiao; Jiajia Dai; Yunfei Ye; Qin Zhang; Zhimin Zhang; Yuhan Jiang; Jia Luo; Jing Hu; Chuan Chen; Ge Wang
Journal:  Clin Epigenetics       Date:  2019-03-04       Impact factor: 6.551

10.  KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells.

Authors:  Madhura Patankar; Sinikka Eskelinen; Anne Tuomisto; Markus J Mäkinen; Tuomo J Karttunen
Journal:  Mol Med Rep       Date:  2019-09-20       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.